NCT06242288

Correlation Between Depression Scores and Serum NF-ĸB/NLRP3 Axis, Biotinidase, and HMGB After Treatment With Isotretinoin in Patients With Acne Vulgaris

Mostafa Bahaa·Phase 3·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov
Study focus
Disease/Condition
Acne Vulgaris
Drug/Device/Intervention
ISOtretinoin 20 MG
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Mostafa Bahaa
Funder
Tanta University
Location
Tanta, Egypt
Timeline & enrollment
Phase
Phase 3
Start date
Jan 30, 2024
End date
Jan 20, 2026
Enrollment
40 participants
Primary outcome

change in biotinidase level

Summary

Acne is a chronic inflammatory disease of the pilosebaceous unit resulting from
 androgen-induced increased sebum production, altered keratinization, inflammation, and
 bacterial colonization of hair follicles on the face, neck, chest, and back by, Cutibacterium
 acnes. Although all age groups can be affected, it is primarily a disease of adolescence.
 Treatment selection is based on disease severity, patient preference, and tolerability.
 Isotretinoin is drug of chioce used for moderate and severe acne. Isotretinoin results in a
 significant reduction in sebum production, influences comedogenesis, lowers surface and
 ductal c. acnes and has anti-inflammatory properties. Biotin deficiency may be caused by
 insufficient dietary uptake of biotin, drug- vitamin interactions and increased biotin
 catabolism during pregnancy and in smokers. Biotin deficiency can also be precipitated by
 decreased activities of biotinidase, which plays a central role in the intestinal absorption
 of biotin

ICD-10 classifications
Acne vulgarisAcneAcne, unspecifiedAcné excoriéeOther acne
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06242288
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06242288 through Pure Global AI's free database. This Phase 3 trial is sponsored by Mostafa Bahaa and is currently Recruiting. The study focuses on Acne Vulgaris. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.